secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0000950170-24-053551
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials
--------------------------------------------------------------------------------

- Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.
- R&D expenses $22.0M in Q1 2024 vs $19.5M in Q1 2023; G&A $7.0M vs $6.2M.
- Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC with EGFR/HER2 mutations; updated data expected H1 2025.
- ORIC-944 initial Phase 1b data supports best-in-class profile; proceeding to combination with AR inhibitor in metastatic prostate cancer.
- Strengthened cash with $125M private placement in January 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/0000950170-24-053551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/oric-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer